Advanced Life Sciences Announces Cethromycin NDA Accepted For Filing By FDA For The Treatment Of Community Acquired Pneumonia

 04.12.2008 04:14   medicalnewstoday.com

Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS), announced that the U.S. Food and Drug Administration (FDA) has accepted and filed the Company's New Drug Application (NDA) for cethromycin, a novel once-a-day oral antibiotic, for the treatment of mild-to-moderate community acquired pneumonia (CAP). The FDA has established a goal of a standard 10-month review such that the anticipated target action date of the cethromycin NDA would be July 31, 2009.

World Infectious Diseases